

Institution	Oklahoma State University - Center for Health Sciences
Meeting Date	Thursday, April 16 2026
Meeting Time	10:00 AM
Meeting Type	Hybrid Meeting

IBC Members Present	Name	Role	Attendance
	Dr. Gerwald Koehler	Committee Chair	Present
	Dr. I-Hsiu (George) Huang	Scientific Member	Present
	Dr. Sue Katz Amburn	Scientific Member	Present
	Dr. Crystal (Niki) Johnson	Scientific Member	Absent
	William (BJ) Reddig	Lab representative	Absent
	Dr. David Wallace	Animal Expert	Present
	Dr. Fang (Fiona) Liu	Non-affiliated member	Present
	Jennifer Nangle	Non-affiliated Member	Absent
	Dr. Vikram Gujar	Alternate Member - Affiliated Scientist	Present, voted as a Scientific Member
Quorum	Quorum is met. The IBC has six (6) voting members present, and four (4) voting members are required to conduct business.		

Others in Attendance	Name	Affiliation	Title
	Kadin Falkensten	Oklahoma State University - Center for Health Sciences	Research Compliance Coordinator, Biosafety Officer

Call to Order	The IBC Chair called this meeting to order at 10:01am.
Conflicts of Interest	The IBC Chair asked all members present to identify any conflicts of interest with the materials that are to be reviewed. Dr. Koehler stated that he will have a conflict of interest in the review of IBC-00001257, and will recuse himself during the discussion of this protocol.
Discussion of previous minutes	No discussion was held regarding the previous minutes; Dr. Katz made the motion to approve the minutes as written, and Dr. Wallace seconded.

Review and Approval of previous meeting minutes	Date of previous meeting Thursday, March 19 2026	Motion Approve as written	Votes; for/against/abstain 6/0/0
---	---	------------------------------	-------------------------------------

Review of Prior Business	Business	Review and Discussion
	Report of pending/outstanding protocol(s)	Two protocols are pending review at the next IBC meeting: an Amendment to IBC-00001216 (PI: Dr. Malabika Maulik) and a new submission, IBC-00001258 (PI: Dr. Malabika Maulik)

New IBC Registrations and Amendments for Review		
Review of IBC-00001184		
PI Name(s)	Dr. Nedra Wilson	
Registration Title/Number	Regulation of ciliary assembly and function in Chlamydomonas	IBC-00001184

Project Overview	<p>Chlamydomonas reinhardtii is an ideal model organism for understanding the molecular mechanisms that underlie the assembly and function of flagella. Flagella, also known as cilia are hair-like cell-surface extensions that contain a core of microtubules. Cilia act as an extracellular antenna, receiving information from the external environment. Multiple cell signaling pathways localized within the cilium are involved in the relay of the external information into the cell body to regulate cellular functions and gene expression. Defects in the normal assembly, regulation, and function of cilia result in a variety of disorders that are collectively termed ciliopathies. To date, more than 20 different ciliopathies have been identified. The identification of at least 190 different gene mutations that result in ciliopathies demonstrate the complexity of cilia. Much of our understanding about ciliary assembly, function, and regulation have come from studies on Chlamydomonas. Chlamydomonas is a unicellular, biciliated green alga whose genome has been sequenced. In addition, the existence of molecular tools including collections of mutants with defects in a variety of flagellar assembly, function, and regulation allows the identification of novel genes involved in ciliary processes. To a large extent, the Chlamydomonas genes are conserved among higher eukaryotes including humans and have led to the identification of genes involved in one or more ciliopathies. In this project, a number of non-viral plasmids will be used to help express specific genes within C. reinhardtii. In addition to these plasmids, C. reinhardtii and E. coli will be used. All plasmids will be wild-type initially, with manipulations made to affect cilia growth. No modifications will be made to the pathogenicity of any agents employed in this protocol. No host/vector systems will be employed in this study. The proposed biosafety level for this study is Biosafety Level 2.</p>
NIH Guidelines Section	III-F1
Risk Assessment and Discussion	<p>Risk Assessment: Generation of splashes, sprays/aerosols from centrifugation</p> <p>Discussion: No additional discussion was held regarding the risk assessment.</p>
Training	<p>All personnel listed on this application have completed the minimum required lab safety training courses, including Lab Chemical safety, Bloodborne Pathogens training, and Laboratory Biosafety training. Additionally, all personnel have documented in-lab training for specific procedures that are carried out in each individual lab.</p>

Additional Training	No additional training was outlined by the IBC for this application.	
Occupational Health Representative Review (if applicable)	No additional occupational health concerns were noted for this application.	
Biosafety Level Assignment	Biosafety Level:	2
	Additional Discussion or notes:	No additional discussion was held regarding the biosafety level.
IBC Vote	Motion:	Approve pending changes 1st: Dr. Wallace 2nd: Dr. Katz
	Votes, for/against/abstain/recused:	6/0/0/0
	Notes:	The following changes were requested: In the Funding section, Please add departmental or intramural funds, if applicable, and remove funding sources that are not funded. In the Experimental Details section, please modify the pbluescript r/sNA listing to correctly state the species of origin and viral fraction of the item. In the Personnel section, please select the activities that each individual will be performing.

Review of IBC-00001257		
PI Name(s)	Dr. Gerwald Koehler	
Registration Title/Number	Candida species infection models and microbial interactions	IBC-00001257

Project Overview	<p>Candida albicans and non-albicans Candida species are important fungal pathogens in immunocompromised individuals. Candidiasis in humans can range from superficial mycoses to deep-seated or disseminated infections with high associated morbidity and mortality. Therefore, the elucidation of the molecular mechanisms of fungal pathogenicity and development of antifungal resistance is crucial for prevention and treatment of infections by Candida species. Beneficial bacteria (probiotics) and their product could provide alternative preventative or treatment approaches for some forms of candidiasis; however, it will be crucial to understand the prerequisites and mechanisms of beneficial actions against the fungi. Interactions between fungal species can also be antagonistic. Screening of fungal species and their secondary metabolites could also reveal novel leads for prevention and treatment of Candida infections. This study will work with a number of agents, including <i>B. subtilis</i>, <i>Lactococcus</i> species, <i>Candida</i> species, <i>Penicillium</i> species, <i>Pichia kudriavzevii</i>, <i>Talaromyces</i> species, and <i>Saccharomyces cerevisiae</i>. Additionally, the nematode <i>Caenorhabditis elegans</i> will be used as an experimental model. Two pre-made plasmids will be purchased and employed to aid in fluorescence and selection of the agents listed. No modifications will be made to nucleic acids or other agents listed here. No host/vector systems will be used during this study. The proposed biosafety level for this study is Biosafety Level 2.</p>
NIH Guidelines Section	III-D-1, III-D-2, III-D-4, Appendix C-I, App C-II, App C-III, App C-VI
Risk Assessment and Discussion	<p>Risk Assessment: Generation of splashes, sprays/aerosols from centrifugation, use of nematodes</p> <p>Discussion: No additional discussion was held regarding the hazardous procedures.</p>
Training	<p>All personnel listed on this application have completed the minimum required lab safety training courses, including Lab Chemical safety, Bloodborne Pathogens training, and Laboratory Biosafety training. Additionally, all personnel have documented in-lab training for specific procedures that are carried out in each individual lab.</p>
Additional Training	<p>No additional training was requested by the IBC.</p>

Occupational Health Representative Review (if applicable)	No additional occupational health concerns were noted.	
Biosafety Level Assignment	Biosafety Level:	2
	Additional Discussion or notes:	No additional discussion was held regarding the biosafety level.
IBC Vote	Motion:	Approve pending changes 1st: Dr. Wallace 2nd: Dr. Gujar
	Votes, for/against/abstain/recused:	5/0/0/1
	Notes:	In the Microorganisms/Agents, additional details section, In the "How long from the time of infection..." text-box, please include a general range of infection based on the person's immune status (e.g. immunocompromised vs. healthy), if such information is available.

New Business	Topic	Discussion
	No new business was discussed at this meeting	
Additional/Other Business	Notice of DMR review/approval of IBC-00001254	The IBC was notified of the designated reviewer's review and approval of the changes to IBC-00001254. No action was needed on the IBC regarding this

	Discussion regarding an inter-committee landing spot for researchers	The IBC discussed the possibility of having a document or webpage that can serve as another place that researchers can go to for information about what types of research need specific committee reviews. This is to further streamline the review processes between committees to ensure that researchers are not going to each committee individually as necessary and can apply to all requisite committees at once. A few ideas were presented, and Kadin Falkensten stated that he will see what can be done regarding this.
--	--	--

Review of Incidents	No incidents were reviewed or discussed at this meeting.
Inspections/Ongoing Oversight	No inspections or ongoing oversight were discussed at this meeting.
IBC Training	No IBC training occurred at this meeting.
Public Comments	No public comments were recorded at this meeting.
Adjournment	The IBC Chair moved to adjourn the meeting at 10:28am The next IBC meeting is scheduled for Thursday, May 21 2026.